An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity | Zendy

Sulabha Ramachandran | Zendy; Daniel Parks | Zendy; Milena Kurtinecz | Zendy; David A. Roth | Zendy; Rafael AlfonsoCristancho | Zendy

Open Access

An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity

Author(s) -

Sulabha Ramachandran,

Daniel Parks,

Milena Kurtinecz,

David A. Roth,

Rafael AlfonsoCristancho

Publication year - 2018

Publication title -

journal of comparative effectiveness research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.567

H-Index - 23

eISSN - 2042-6313

pISSN - 2042-6305

DOI - 10.2217/cer-2017-0085

Subject(s) - belimumab , medicine , placebo , randomized controlled trial , bliss , clinical trial , gastroenterology , immunology , antibody , pathology , b cell activating factor , alternative medicine , b cell , computer science , programming language

Aim: To compare the efficacy of intravenous (IV) and subcutaneous (SC) belimumab plus standard therapy in patients with active, autoantibody-positive systemic lupus erythematosus and high disease activity (HDA). Patients & methods: An indirect treatment comparison using patient-level data of patients with HDA from three belimumab IV Phase III randomized controlled trials (BLISS-52 [BEL110751]; BLISS-76 [BEL110752]; Northeast Asia study [BEL113750]) and one belimumab SC randomized controlled trial (BLISS-SC [BEL112341]). Results: Similar efficacy results were identified between the belimumab formulations and greater improvements in efficacy endpoints were observed for both formulations compared with placebo. Conclusion: This indirect treatment comparison provides further evidence of the efficacy of belimumab IV and SC in patients with systemic lupus erythematosus and HDA, compared with standard therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research